BioWorld

Dec. 3, 2008

Titan, Targeted Genetics, InSite Cut Staff; Enzon Nixes Spin-off

A day after the National Bureau of Economic Research declared the last 12 months an official recession, the restructuring parade for biotech continues, as firms try to stretch their limited capital as far as possible. (BioWorld Today) Read More

XenoPort's Shares Plummet on Failed GERD Drug Trial

FDA Gives TransMolecular OK for Phase III Brain Cancer Study

NewCo News: Zacharon Pharma Targets Glycans with Small Molecules

Corrections & Clarifications

Horizon's HZT-501 Reduces GI Ulcers in Pivotal Studies in Pain

Clinic Roundup

Other News To Note

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for July 17, 2026.

ALN-5288 lowers tau levels in preclinical models

BioWorld Science

Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....

Elderly hands holding broken brain structure

Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability

BioWorld Science

Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...

Capital remains selective in ‘barbell’ biotech market

BioWorld

Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...

Brush scrubbing brain figurine with soap

PSB-229 reduces plaque burden in Alzheimer’s models

BioWorld Science

Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...